ARUP Welcomes New CEO, Edgar Braendle, M.D., Ph.D.
Aug 18, 2016 2:03 PM
I recognized the value of ARUP Laboratories as a critical partner in transforming health care when I joined the University of Utah five years ago. Having an on-site laboratory with nationally sought after expertise in pinpointing the causes of disease is critical for our patients—bringing them back to wellness and keeping them healthy. The unique ability of ARUP scientists to develop new diagnostic tests has been helping patients all over the country and is central to the principle of personalized medicine and personalized health. Started in 1984 by the University of Utah’s Department of Pathology as a nonprofit organization, ARUP has since established a distinguished reputation for quality among the nation’s leading national reference laboratories—right here in our own backyard. So it’s no wonder we’ve had the good fortune of landing a highly accomplished and successful physician-scientist to lead ARUP into the future. Edgar Braendle, M.D., Ph.D., started as ARUP’s chief executive officer on Aug. 16.
Dr. Braendle joins us with superb experience as both a scientist and top-level administrator in the pharmaceutical industry. He has received recognition in his career for a distinctive focus on the clinical benefit of translational science for patients. Trained in urology, oncology, and pharmacology, Dr. Braendle launched and grew the new division of Companion Diagnostics at the Swiss-based drug company Novartis Pharmaceutical Corp, most recently serving as senior vice president and global director. His work to lead the development of companion diagnostics in conjunction with drug development, showed early appreciation of the importance of targeting the right drugs to the right patients at the right doses. This methodology represents a central component of personalized or precision medicine. Dr. Braendle’s experience in this area has given him expertise in drug and test development, core services that ARUP provides, as well as in the complex regulatory issues a national reference laboratory must navigate in its daily business. His background also clearly opens new opportunities for partnerships between ARUP and the pharmaceutical industry.
Dr. Braendle’s academic experience runs deep as well. He earned his medical degree from RWTH Aachen University in Germany and then received specialized training in oncology, urology and pharmacology. While on faculty at the University of Ulm, he led a research laboratory and phase-1 clinical trials unit. His pharmaceutical career included leadership positions in molecular diagnostics and oncology biologics at Novartis and at Schering AG, a multinational German pharmaceutical company acquired by Bayer AG.
All of this experience is key to reshaping the role of diagnostics in the face of reform. A unique hybrid of academic and business innovation, ARUP offers more than 3,000 tests in genetics, infectious diseases, oncology, pain management and immunology, with nationwide clients that include major health care systems, top teaching and children’s hospitals, commercial laboratories, the military, and government and non-government agencies. Approximately 50,000 tubes of blood and tissue specimens arrive at the laboratory every day for analysis from around the entire nation.
As ARUP’s era under Dr. Braendle begins, I give my heartfelt thanks to Dean Y. Li, M.D., Ph.D., the University’s health sciences associate vice president for research and chief scientific officer, who so ably filled the role of interim CEO during the past year. While overseeing the health sciences’ research enterprise, Dr. Li successfully advocated for and guided ARUP during our search to find a new permanent CEO.
As ARUP expands its services and offerings under Dr. Braendle’s leadership, I look forward to forming an even closer partnership between the University Health Sciences and the laboratory. Playing on each other’s strengths, I believe we can make a lasting impact to improve the health of Utahns and people everywhere.comments powered by Disqus